Digital age in precision oncology
Precision Oncology Program
A solution to select
personalized treatments
Scientifically
proven
In any types
of tumors
Partnership of BC Platforms, Euformatics, and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals
BC Platforms, Euformatics and Oncompass Medicine form a partnership to develop oncology NGS workflows for buyer consortium of seven major European hospitals
A Hungarian participant will also attend the Washington summit on artificial intelligence
How can we help?
Our Precision Oncology Program presents the possibilities of personalized targeted treatments for cancer patients.
All cancers have genetic components though most are not inherited. Personalized targeted treatments are now available for many of these genetic defects contributing to tumorigenesis. Molecular diagnostics reveals the underlying cause of tumor development.
Based on the identified gene defects a proprietary oncology AI software determines both the molecular targets and its' associated personalized targeted compounds. A number of conditions need to be met for personalized oncology care. In order to best assess them, make an appointment for a consultation.
Who can we help?
The personalized treatment plan can be determined for any given tumor type as long as the targeted treatments for the identified gene defects are available.
The following factors and more are taken into consideration for program planning: cancer type, previous molecular diagnostic results, available clinical history, performance status, ability and willingness to travel, and risk of recurrence. Advisory board approved recommendations from the oncology community provide us with guidance for molecular diagnotics based personalized treatment planning. Online and in-person consultations are available for program planning and selection.
Digital Therapy Planning in Precision Oncology
"Every patients’ tumor harbors an individual combination of 4-5 mutations out of 6 million potential mutations of 600 genes. There are already 100 targeted therapies in clinical use, and there are around 1000 in clinical development.
The challenge of precision oncology is choosing which mutant gene to target with which targeted therapy to achieve response in the presence of the specific mutation and all the other mutant genes. We have to select an effective treatment for the given mutation based on the targeted unique gene mutation. The solution to this problem is the help of artificial intelligence. Oncompass Medicine developed a medical software system to select the most appropriate molecular-based targeted treatment options for cancer patients."
— István Petak MD PhD (Oncompass)
The story of Katalin
The cancer survivor lady's book is published
The story of a pharmacist, whose lung cancer metastasized to her bone and brain, inspires everyone.
More information
Personalized therapies
Katalin has been symptom-free for 10 years this year, recovering from metastatic lung cancer with the help of Oncompass Medicine
Proceed
Digital therapy planning - How does precision oncology decision support help treating oncologists?
Proceed
Molecular diagnostics and targeted treatment of ovarian cancer
Proceed
Molecular diagnostics and targeted treatment of melanoma
Proceed
Molecular diagnostics and treatment of pancreas and bile ducts
ProceedAbout the AI-based software we use
Genomate AI
Oncompass Medicine developed a medical software system with the purpose of best selecting molecular-based targeted treatment options for cancer patients. The tool is designed to support oncologists in selecting the most effective personalized therapy for their cancer patients.
The software now is further developed by Genomate Health Inc., a Boston-based biotechnology company founded by Istvan Petak and Oncompass Medicine.
1.900+
compounds
59.000+
Gene mutation
12.000+
scientific evidence
450+
type of cancer
1.800+
clinical trial
21.000+
decision rules
